Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma

Cancer

Volumn 101, Issue 8, 2004, Pages 1809-1817

  Van Den Broek, Guido B ^a,b   Rasch, Coen R N ^a   Pameijer, Frank A ^a   Peter, Ellen ^a   Van Den Brekel, Michiel W M ^a,b   Tan, I Bing ^a,b   Schornagel, Jan H ^a   De Bois, Josien A ^a   Zijp, Lambert J ^a   Balm, Alfons J M ^a,b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Chemoradiation; Head and neck neoplasms; Intraarterial infusions; Prognostic factors; Selective targeted chemoradiation (RADPLAT); Tumor volume

Indexed keywords

CISPLATIN; GADOLINIUM; HEMOGLOBIN; SODIUM THIOSULFATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; FEMALE; FOLLOW UP; GLOSSECTOMY; HEAD AND NECK CANCER; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR VOLUME; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRA-ARTERIAL; LYMPH NODES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROBABILITY; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 4744355864     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20556     Document Type: Article

References (42)

1. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res. 1998;18:4779-4786.
2. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-98.
3. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798-1804.
4. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081-2086.
5. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76.
6. Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic L, Milicic B, Nikolic N. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol. 1997;43:29-37.
7. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-955.
8. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998;16:1318-1324.
9. Fein DA, Lee WR, Hanlon AL, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol. 1995;13:2077-2083.
10. Warde P, O'Sullivan B, Bristow RG, et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys. 1998;41:347-353.
11. Daly T, Poulsen MG, Denham JW, et al. The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 2003;68:113-122.
12. Singh B, Bhaya M, Zimbler M, et al. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck. 1998;20:1-7.
13. Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Mancuso AA. Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck. 2003;25:535-542.
14. O'Brien CJ, Lauer CS, Fredricks S, et al. Tumor thickness influences prognosis of T1 and T2 oral cavity cancer-but what thickness? Head Neck. 2003;25:937-945.
15. Jose J, Coatesworth AP, Johnston C, MacLennan K. Cervical node metastases in squamous cell carcinoma of the upper aerodigestive tract: the significance of extracapsular spread and soft tissue deposits. Head Neck. 2003;25:451-456.
16. Myers JN, Greenberg JS, Mo V, Roberts D. Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer. 2001;92:3030-3036.
17. Sobin LH, Wittekind CH, editors. TNM classification of malignant tumours, 5th edition. New York: John Wiley & Sons, Inc., 1997.
18. Balm AJM, Rasch CRN, Schornagel JH, et al. High dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck. 2004;26:485-493.
19. Robbins KT, Kumar P, Wong FS, et al. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck. 2000;22:687-693.
20. Robbins KT, Kumar P, Regine WF, et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys. 1997;38:263-271.
21. Gemmete JJ. Complications associated with selective high-dose intraarterial cisplatin and concomitant radiation therapy for advanced head and neck cancer. J Vasc Interv Radiol. 2003;14:743-748.
22. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187-220.
23. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
24. Doweck I, Denys D, Robbins KT. Tumor volume predicts outcome for advanced head and neck cancer treated with targeted chemoradiotherapy. Laryngoscope. 2002;112:1742-1749.
25. Hermans R, Op de Beeck K, Van den Bogaert W, et al. The relation of CT-determined tumor parameters and local and regional outcome of tonsillar cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys. 2001;50:37-45.
26. Nathu RM, Mancuso AA, Zhu TC, Mendenhall WM. The impact of primary tumor volume on local control for oropharyngeal squamous cell carcinoma treated with radiotherapy. Head Neck. 2000;22:1-5.
27. Hermans R, Van den Bogaert W, Rijnders A, Doornaert P, Baert AL. Predicting the local outcome of glottic squamous cell carcinoma after definitive radiation therapy: value of computed tomography-determined tumour parameters. Radiother Oncol. 1999;50:39-46.
28. Hermans R, Van den Bogaert W, Rijnders A, Baert AL. Value of computed tomography as outcome predictor of supraglottic squamous cell carcinoma treated by definitive radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:755-765.
29. Castelijns JA, van den Brekel MW, Smit EM, et al. Predictive value of MR imaging-dependent and non-MR imaging-dependent parameters for recurrence of laryngeal cancer after radiation therapy. Radiology. 1995;196:735-739.
30. Mendenhall WM, Parsons JT, Mancuso AA, Pameijer FA, Stringer SP, Cassisi NJ. Definitive radiotherapy for T3 squamous cell carcinoma of the glottic larynx. J Clin Oncol. 1997;15:2394-2402.
31. Freeman DE, Mancuso AA, Parsons JT, Mendenhall WM, Million RR. Irradiation alone for supraglottic larynx carcinoma: can CT findings predict treatment results? Int J Radiat Oncol Biol Phys. 1990;19:485-490.
32. Mancuso AA, Mukherji SK, Schmalfuss I, et al. Preradiotherapy computed tomography as a predictor of local control in supraglottic carcinoma. J Clin Oncol. 1999;17:631-637.
33. Pameijer FA, Mancuso AA, Mendenhall WM, Parsons JT, Kubilis PS. Can pretreatment computed tomography predict local control in T3 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy? Int J Radiat Oncol Biol Phys. 1997;37:1011-1021.
34. Pameijer FA, Mancuso AA, Mendenhall WM, et al. Evaluation of pretreatment computed tomography as a predictor of local control in T1/T2 pyriform sinus carcinoma treated with definitive radiotherapy. Head Neck. 1998;20:159-168.
35. Gilbert RW, Birt D, Shulman H, et al. Correlation of tumor volume with local control in laryngeal carcinoma treated by radiotherapy. Ann Otol Rhinol Laryngol. 1987;96:514-518.
36. Kraas JR, Underhill TE, D'Agostino RB Jr., Williams DW III, Cox JA, Greven KM. Quantitative analysis from CT is prognostic for local control of supraglottic carcinoma. Head Neck. 2001;23:1031-1036.
37. Chen AY, Matson LK, Roberts D, Goepfert H. The significance of comorbidity in advanced laryngeal cancer. Head Neck. 2001;23:566-572.
38. Piccirillo JF, Lacy PD, Basu A, Spitznagel EL. Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg. 2002;128:1172-1179.
39. Reid BC, Alberg AJ, Klassen AC, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer. 2001;92:2109-2116.
40. van Bokhorst-de van der Schueren MA, van Leeuwen PA, Kuik DJ, et al. The impact of nutritional status on the prognoses of patients with advanced head and neck cancer. Cancer. 1999;86:519-527.
41. Doweck I, Robbins KT, Vieira F. Analysis of risk factors predictive of distant failure after targeted chemoradiation for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2001;127:1315-1318.
42. de Bree R, Deurloo EE, Snow GB, Leemans CR. Screening for distant metastases in patients with head and neck cancer. Laryngoscope. 2000;110:397-401.